Previous 10 | Next 10 |
All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated N-803 is being studied in three other HIV cure-related clinical trials ImmunityBio ( NASDAQ: IBRX ), a clinical-stage...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-23 17:39:49 ET Gainers: Sizzle Acquisition ( SZZL ) +12% . ImmunityBio ( IBRX ) +6% . E.W. Scripps ( SSP ) +5% . Outset Medical ( OM ) +5% . BigCommerce Holdings. ( BIGC ) +5% . Losers: EverQuote...
The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) comprising a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803 could potentially prevent colon an...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
2024-02-11 02:41:56 ET Summary Pre-PDUFA positioning is a good opportunity to buy ImmunityBio stock at a low price. Multiple catalysts could drive the stock price higher over the next 24 months. ImmunityBio has the potential to become a big pharma company rather than being sol...
Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global health in patients who completed PRO questionnaires and reached month 24 on-study Overall, participants with complete responses (CRs) to combination...
2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...
2024-01-25 14:20:00 ET Summary With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year’s most highly anticipated IPOs. The company’s lead drug targets a sizable addressable market (NMIBC) where there is an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...